BOTHELL, Wash., Nov. 12 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) announced today that representatives from its research and development team will be attending the 2008 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting to be held November, 16-20, 2008 at the Georgia World Congress Center in Atlanta, GA.

SCOLR Pharma will be exhibiting at the AAPS show in booth #708 where its representatives will be available to engage the pharmaceutical scientific community about applications of its patented, CDT(R) oral drug delivery technologies. The Company will also make a total of eight poster presentations over three days, one of which will focus on its 12-hour extended-release (ER) ibuprofen for the over-the-counter (OTC) market. Ibuprofen is an analgesic that is sold in immediate-dose products as Advil(R) and Motrin(R), among others, as well as generically. SCOLR recently reported favorable top-line results from its pivotal Phase III trial to evaluate the safety and efficacy of its 12 hour CDT 600 mg ER ibuprofen for the OTC market. The trial incorporated FDA special protocol assessment design elements, met both co-primary endpoints (p<0.0001), and had no significant adverse events.

SCOLR Pharma will make the following eight poster presentations at the 2008 AAPS annual meeting:

1. "Encapsulation as a Means to Control the Release of Oil and Improve Shelf Life Stability" Illustrating SCOLR's novel work with challenging formulations for oil based active ingredients.
2. "Development of Fenofibrate Immediate-Release Tablets Using Hot-Melt Technology" Demonstrating unique formulation work for a recent fenofibrate formulation.
3. "Evaluation of the Geometric Proportionality of a Sustained-Release Ibuprofen Matrix Tablet" Demonstrating the flexibility of SCOLR's novel 12-hour sustained-release ibuprofen formulation.
4. "Formulation of "Mini-Tablets" in a Capsule for Alternate Routes of Administration" Demonstrating the broad potential of SCOLR's oral technologies for challenging formulations.
5. "Design of a Controlled-Release Naproxen Sodium Solid Oral Dosage" Demonstrating recent work developing a novel sustained-release naproxen sodium formulation.
6. "Effect of Permeability Enhancers for Polar Drug Transport Across Caco-II Cell Monolayers" Illustrating novel work conducted at SCOLR in support permeability enhancement formulations.
7. "Development of A Self-Emulsifying Raloxifene HCl Liquid Formulation" Highlighting SCOLR's novel work with emulsion and self-emulsifying oral formulations.
8. "Sinker Evaluation of "Mini-Tablet "Filled Capsules of an Extended-Release Formulation" Showcasing SCOLR's work with analytical methods.

About SCOLR Pharma

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.373.0171 or visit http://www.scolr.com/.

    Contacts:
    Investor Relations:
    Cameron Associates
    Kevin McGrath
    212.245.4577
    Kevin@cameronassoc.com

SOURCE SCOLR Pharma, Inc.